
Raghuram Koganti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5530799/publications.pdf Version: 2024-02-01



RACHURAM KOCANTI

#	Article	IF	CITATIONS
1	Herpes Simplex Virus Cell Entry Mechanisms: An Update. Frontiers in Cellular and Infection Microbiology, 2020, 10, 617578.	1.8	67
2	Dysregulation of Cell Signaling by SARS-CoV-2. Trends in Microbiology, 2021, 29, 224-237.	3.5	62
3	Current and Emerging Therapies for Ocular Herpes Simplex Virus Type-1 Infections. Microorganisms, 2019, 7, 429.	1.6	59
4	Vaccines and Therapies in Development for SARS-CoV-2 Infections. Journal of Clinical Medicine, 2020, 9, 1885.	1.0	46
5	Role of Tunneling Nanotubes in Viral Infection, Neurodegenerative Disease, and Cancer. Frontiers in Immunology, 2021, 12, 680891.	2.2	45
6	Heparanase, cell signaling, and viral infections. Cellular and Molecular Life Sciences, 2020, 77, 5059-5077.	2.4	38
7	Heparanase-Regulated Syndecan-1 Shedding Facilitates Herpes Simplex Virus 1 Egress. Journal of Virology, 2020, 94, .	1.5	31
8	Pathobiology and treatment of viral keratitis. Experimental Eye Research, 2021, 205, 108483.	1.2	23
9	Prior inhibition of AKT phosphorylation by BX795 can define a safer strategy to prevent herpes simplex virus-1 infection of the eye. Ocular Surface, 2020, 18, 221-230.	2.2	18
10	Standalone or combinatorial phenylbutyrate therapy shows excellent antiviral activity and mimics CREB3 silencing. Science Advances, 2020, 6, .	4.7	12
11	Emerging Roles of Heparan Sulfate Proteoglycans in Viral Pathogenesis. Seminars in Thrombosis and Hemostasis, 2021, 47, 283-294.	1.5	12
12	Pharmaceutically Acceptable Carboxylic Acid-Terminated Polymers Show Activity and Selectivity against HSV-1 and HSV-2 and Synergy with Antiviral Drugs. ACS Infectious Diseases, 2020, 6, 2926-2937.	1.8	11
13	Heparan Sulfate Binding Cationic Peptides Restrict SARS-CoV-2 Entry. Pathogens, 2021, 10, 803.	1.2	5
14	BX795-Organic Acid Coevaporates: Evaluation of Solid-State Characteristics, In Vitro Cytocompatibility and In Vitro Activity against HSV-1 and HSV-2. Pharmaceutics, 2021, 13, 1920.	2.0	5
15	Intrinsic Antiviral Activity of Optineurin Prevents Hyperproliferation of a Primary Herpes Simplex Virus Type 2 Infection. Journal of Immunology, 2022, 208, 63-73.	0.4	5
16	mTORC2 confers neuroprotection and potentiates immunity during virus infection. Nature Communications, 2021, 12, 6020.	5.8	3
17	Infection-Induced Porcine Ex Vivo Corneal Wound Model to Study the Efficacy of Herpes Simplex Virus-1 Entry and Replication Inhibitors. Methods in Molecular Biology, 2021, 2193, 183-196.	0.4	1